Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 31, 2000Journal of Medicinal ChemistryOpen Access

BCX-1812 (RWJ-270201):  Discovery of a Novel, Highly Potent, Orally Active, and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug Design

View Full Paper
Ask AI
Bookmark
Share

Authors

YBY.S. BabuBioCryst Pharmaceuticals (United States)PCPooran ChandSardar Vallabhbhai Patel University of Agriculture & TechnologySBShanta BantiaBioCryst Pharmaceuticals (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Babu et al. (2000) studied this question.

synapsesocial.com/papers/6a701620e5469ee92be0dae5https://doi.org/10.1021/jm0002679
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Uptake, Metabolism and Excretion of Orally and Intravenously Administered, Double‐Labeled N‐GIycoloylneuraminic Acid and Single‐Labeled 2‐Deoxy‐2,3–dehydro‐N‐acetylneuraminic Acid in Mouse and Rat1982 · 68 citations
  2. 2SERIOUS MORBIDITY AND MORTALITY ASSOCIATED WITH INFLUENZA EPIDEMICS1982 · 448 citations